{{Rsnum
|rsid=12639920
|Gene=ATP8A1
|Chromosome=4
|position=42410670
|Orientation=plus
|GMAF=0.3581
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
|Gene_s=ATP8A1
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 45.1 | 46.0 | 8.8
| HCB | 75.9 | 24.1 | 0.0
| JPT | 74.3 | 25.7 | 0.0
| YRI | 2.7 | 27.9 | 69.4
| ASW | 8.8 | 40.4 | 50.9
| CHB | 75.9 | 24.1 | 0.0
| CHD | 84.4 | 12.8 | 2.8
| GIH | 50.5 | 41.6 | 7.9
| LWK | 5.6 | 37.0 | 57.4
| MEX | 48.3 | 36.2 | 15.5
| MKK | 18.6 | 50.6 | 30.8
| TSI | 52.9 | 41.2 | 5.9
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs12639920
|Name_s=
|Gene_s=ATP8A1
|Feature=
|Evidence=PubMed ID:19118814
|Annotation=This variant is significantly associated with late-onset Alzheimer disease (LOAD) in a GWAS study with 492 LOAD cases and 498 cognitive controls using Illumina's HumanHap550 beadchip.
|Drugs=
|Drug Classes=
|Diseases=Alzheimer Disease
|Curation Level=Curated
|PharmGKB Accession ID=PA162363817
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs12639920
|overall_frequency_n=74
|overall_frequency_d=128
|overall_frequency=0.578125
|n_genomes=39
|n_genomes_annotated=0
|n_haplomes=58
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}